Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Programmed death-ligand 1 (PD-L1) expression on tumor cells (TCs) by immunohistochemistry is rapidly gaining importance as a diagnostic for the selection or stratification of patients with non-small cell lung cancer (NSCLC) most likely to respond to single-agent checkpoint inhibitors. However, at le...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2018
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205493/
https://ncbi.nlm.nih.gov/pubmed/30297397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1802166115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados